New Research Explores on Pancreatic Ductal Adenocarcinoma - Pipeline Review, H2 2016

Pancreatic Ductal Adenocarcinoma - Pipeline Review, H2 2016 is a new market research publication announced by Reportstack. This report provides an overview of the Pancreatic Ductal Adenocarcinoma (Oncology) pipeline landscape.

Pancreatic ductal adenocarcinoma is a malignant neoplasm that affects pancreas. Symptoms include upper abdominal pain that may radiate to back, yellowing of skin and the whites of eyes (jaundice), loss of appetite, weight loss, depression, blood clots. Predisposing factors include smoking, alcohol abuse, obesity, family history, age, chronic pancreatitis and diabetes. Treatment includes chemotherapy and radiation therapy.

Complete report available @ Pancreatic Ductal Adenocarcinoma - Pipeline Review, H2 2016

Report Highlights

This report provides comprehensive information on the therapeutics under development for Pancreatic Ductal Adenocarcinoma (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Pancreatic Ductal Adenocarcinoma (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Pancreatic Ductal Adenocarcinoma and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed and Preclinical stages are 4, 12, 15, 1 and 15 respectively for Similarly, the Universities portfolio in Phase II, Preclinical and Discovery stages comprises 1, 1 and 1 molecules, respectively for Pancreatic Ductal Adenocarcinoma.

Pancreatic Ductal Adenocarcinoma (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from a proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Pancreatic Ductal Adenocarcinoma (Oncology).
- The pipeline guide reviews pipeline therapeutics for Pancreatic Ductal Adenocarcinoma (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources. 
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Pancreatic Ductal Adenocarcinoma (Oncology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Pancreatic Ductal Adenocarcinoma (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects. 
- The pipeline guide reviews latest news related to pipeline therapeutics for Pancreatic Ductal Adenocarcinoma (Oncology)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Pancreatic Ductal Adenocarcinoma (Oncology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Pancreatic Ductal Adenocarcinoma (Oncology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Companies Mentioned

BerGenBio AS BioNTech AG Celgene Corporation Clovis Oncology, Inc. COARE Biotechnology, Inc. Concordia International Corp Eli Lilly and Company FibroGen, Inc. Gilead Sciences, Inc. Halozyme Therapeutics, Inc. Immodulon Therapeutics Ltd. Immunomedics, Inc. Incuron, LLC Incyte Corporation Inflection Biosciences Limited Inovio Pharmaceuticals, Inc. InvivoGen Therapeutics MedImmune, LLC Medisyn Technologies, Inc. Merck & Co., Inc. Nerviano Medical Sciences S.r.l. Novartis AG OncoMed Pharmaceuticals, Inc. Ono Pharmaceutical Co., Ltd. Oryx GmbH & Co. KG Pfizer Inc. Quest PharmaTech Inc. Sillajen Biotherapeutics Soricimed Biopharma Inc. Sun BioPharma, Inc. Swedish Orphan Biovitrum AB Tara Immuno-Oncology Therapeutics LLC Tokai Pharmaceuticals, Inc.

Contact:

Debora White

Manager - Marketing

debora@reportstack.com

Ph: +1-888-789-6604

ReportstackMarket Research

###